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CD25a b s t r a c t
Objective: To study the role of urinary interferon gamma-induced protein 10 (IP-10) and urinary soluble
CD 25 (sCD 25) as diagnostic and prognostic markers of lupus nephritis (LN) and their relation to the LN
class in renal biopsy.
Subjects and methods: This study included 45 lupus patients fulfilling the Systemic Lupus International
Collaborating Clinics (SLICC) classification criteria: 25 patients with active LN during activity and during
follow up (3 months later) as [group A] and 20 patients without any signs of activity [group B]. (20) age
and sex matched healthy subjects were enrolled as control group [group C]. Urine samples were collected
at baseline and at follow up. Urinary IP-10 and sCD25 were measured by ELISA.
Results: Urinary IP-10 and sCD25 levels were higher in group A compared to groups B and C (P < 0.001 for
both). In patients with active nephritis, urinary IP-10 and sCD25 correlated positively with serum crea-
tinine (P < 0.001 for both), proteinuria (p = 0.010; p = 0.007), anti ds-DNA (p = 0.002; p < 0.001), SLEDAI
score (global) (P < 0.001 for both), and renal SLEDAI score (p = 0.002; p < 0.001) respectively. The urinary
IP-10 and sCD25 levels were highest in patients with class (IV) LN and lowest in class (II) patients with a
statistically significant difference. In patients achieving remission with treatment, both markers
decreased significantly.
Conclusion: Urinary IP-10 and sCD25 are potential biomarkers for early recognition and follow up of LN.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lupus nephritis (LN) is a serious complication of systemic lupus
erythematosus (SLE) affecting 23–66% of lupus patients.1 But with
the use of immunosuppressive regimens, renal affection and
patient survival are improving.2 LN pathogenesis is a complicated
process, including glomerular deposition of autoantibodies, com-
plement activation, cellular proliferation, release of chemokines
and proinflammatory cytokines leading to inflammation and fibro-
sis.3 Although, kidney biopsy provides evidence for LN diagnosis,
prognosis, activity, chronicity and planning of therapy, it is an inva-
sive procedure with its own complications. Thus, the discovery ofnew biomarkers can facilitate early diagnosis, assessing disease
severity and predicting disease outcome.4
C-X-C motif chemokine 10 (CXCL10) also known as interferon
c-induced protein 10 (IP-10) is one of the CXC chemokine family.5
CXCL10 chemoattracts macrophages, dendritic cells, NK cells and
activated T lymphocytes toward sites of inflammation.6 CXCL10
is a pleiotropic molecule capable of exerting potent biological func-
tions, including promoting the chemotactic activity of CXCR3+
cells, inducing apoptosis, regulating cell growth and proliferation
as well as angiogenesis in infectious and inflammatory diseases
and cancer.7,8 Serum CXCL 10 levels are elevated in lupus patients
and correlate with disease activity.9
CD25 represents the a-chain of the interleukin-2 receptor
(IL-2Ra), a low affinity binding receptor.10 IL-2 is secreted after
T-cell activation playing an important role in growth, proliferation
and differentiation of T cells converting them to effector T cells.
sCD25 can be measured in serum as well as in body fluid as a
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flares and decline with treatment and clinical improvement sug-
gesting that sCD25 can be considered a promising candidate bio-
marker for disease activity in patients with SLE, especially among
those with kidney involvement.122. Subjects and methods
2.1. Subjects
This study included 45 patients with SLE fulfilling the Systemic
Lupus International Collaborating Clinics (SLICC) classification cri-
teria for diagnosis of SLE13 classified into 25 patients with active
lupus nephritis during activity and during follow up (3 months
later) as [group A] and 20 patients without any signs of activity
as [group B]. Twenty age and sex matched healthy subjects were
enrolled as control group [group C]. Patients were recruited from
the outpatient clinic and the inpatient ward of the internal medi-
cine department at Alexandria Main University Hospital after the
approval of the ethical committee. Exclusion criteria were diabetes
mellitus, sepsis, hepatitis C virus infection, renal transplantation
and tuberculosis. The study was conducted in accordance with
the ethical guidelines of the 1975 Declaration of Helsinki and
informed consent was obtained from each patient.
2.2. Methods
All groups were subjected to full history taking, full clinical
examination and assessment of disease activity by applying the
score of SLE disease activity index (SLEDAI).14 Assessment of renal
disease activity was done by applying the renal SLEDAI score.15
Laboratory investigations included CBC, ESR, serum creatinine,
blood urea, 24 h urinary protein, complete urine analysis, serum
complement levels C3 and C4, serum ANA and serum anti ds-
DNA titres by specific enzyme-linked immunosorbent assay
(ELISA) method (ORGENTEC Diagnostika CO., Mainz, Germany).
Renal biopsy was performed to all SLE patients with clinical and
laboratory evidence of renal involvement. Determination of the
activity and chronicity indices was performed according to the
scheme of the International Society of Nephrology/Renal Pathology
Society (ISN/RPS) 2003 classification of lupus nephritis.16
In group A patients, induction therapy was started using intra-
venous methyl prednisolone (0.51 gm for 3 days) and intravenous
cyclophosphamide (0.5 gm) every 2 weeks for 3 months (Euro-
Lupus regimen).17 Patients were assessed 3 months later (follow
up) to determine their response to treatment. Complete remission
was defined when serum creatinine returned to previous baseline
and urine protein:creatinine ratio declined to <500 mg/g. Partial
remission was defined as having stabilization (±25%) or improve-
ment of serum creatinine, but not to normal, and ˃50% reduction
in urine protein:creatinine ratio.18
2.3. Urine sample collection and biochemical analysis
Urine was collected in a sterile container and centrifuged for
20 min at 2000–3000 r.p.m. Supernatant was removed. If precipita-
tion appeared, centrifugation of the sample was done again. The
levels of urinary IP-10 and sCD25 were measured by ELISA (Assay
Kit CO., Sunnyvale, CA, USA) according to the manufacturer’s
instructions.
2.4. Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0. Qualitative data were describedusing number and percent and were compared using Chi square
test. Student’s t test and F-test (ANOVA) were used to compare
between normally distributed quantitative data, which were
expressed in mean ± standard deviation (SD). Mann–Whitney test
and Kruskal Wallis test were used to compare abnormally dis-
tributed quantitative variables, which were expressed in median,
minimum and maximum. Correlations between two quantitative
variables were assessed using Spearman coefficient. Receiver oper-
ating characteristic (ROC) analysis and difference between area
under the curve (AUC) were performed by MedCalc, version 15.8.
Significance of the obtained results was judged at the 5% level. P
value < 0.05 was considered as significant.3. Results
3.1. Baseline characteristics of patients
The study included 45 SLE patients (active nephritis, inactive
SLE) (5 males, 40 females) with a mean age of (27.96 ± 7.98) years
in group A, (30.25 ± 10.05) years in group B and (24.70 ± 6.42)
years in group C (healthy controls). There was no statistically sig-
nificant difference between different groups regarding age and
sex. Clinical and laboratory data of patients and control group
are shown in Table 1.3.2. Urinary IP-10 and sCD25 levels
Urinary IP-10 and sCD25 levels were significantly higher in
group A (active nephritis) than in groups B (inactive) and C (con-
trol) (P < 0.001) and both were higher in group B than group C with
P values of (0.001) and (<0.001) respectively (Fig. 1).3.3. Correlation between urinary IP-10 and sCD25 with different
parameters
In active nephritis group (A), there was significant positive cor-
relation between urinary IP-10 and sCD25 with serum creatinine
(Figs. 2a and 3a), proteinuria (Figs. 2b and 3b), anti ds-DNA
(Figs. 2c and 3c) and SLEDAI score (global) (Figs. 2d and 3d). Also,
renal SLEDAI score showed a positive correlation with both mark-
ers (r = 0.586, p = 0.002; r = 0.844, p < 0.001). In addition, there was
negative correlation between urinary IP-10 with serum C3 and C4
but it was insignificant (r = 0.376, p = 0.064; r = 0.162,
p = 0.439). On the other hand, the correlation between urinary
sCD25 with serum C3 and C4 was significant (r = 0.479,
p = 0.015; r = 0.492, p = 0.012).3.4. Renal biopsy and its relation to the urinary markers
Renal biopsy was done for all patients in group A (active nephri-
tis) with 2 (8%) patients had class II LN, 7 (28%) had class III (±V) LN,
14 (56%) had class IV (±V) LN and 2 (8%) had class V LN. Activity
index of renal biopsy ranged from 5 to 12 with a median value of
8, while the chronicity index ranged from 1 to 5 with a median
value of 3.
Urinary IP-10 and sCD25 were higher in patients with diffuse
proliferative GN (class IV) than in focal proliferative GN (class III)
patients while those with the non-proliferative forms of lupus
nephritis (class II and V) had the lowest levels of IP-10
(p = 0.011) and sCD25 (p = 0.001), with a statistically significant
difference (Table 2). In addition, there was a positive correlation
between urinary IP-10 and sCD25 with activity (r = 0.677,
p < 0.001; r = 0.736, p < 0.001) and chronicity indices (r = 0.647,
p < 0.001; r = 0.677, p < 0.001) of renal biopsy.
Table 1











Age (years) 27.96 ± 7.98 30.25 ± 10.05 24.70 ± 6.42 0.110
Female: Male 22:3 18:2 18:2 1.000
Duration of disease (years) 2 (0.08–15) 4.75 (1–15) – 0.001*
Creatinine (mg/dl) 2.7 (0.8–8) 0.8 (0.6–1.10) 0.85 (0.6–1.1) <0.001*
24 hr urine protein (gm/day) 3.2 (1–10) 0.1 (0.09–0.14) 0.10 (0.08–0.12) <0.001*
Anti-dsDNA (IU/ml) 323 (150–570) 21.5 (12–35) – <0.001*
C3 (mg/dl) 38.68 ± 13.20 139.1 ± 23.60 140.2 ± 22.05 <0.001*
C4 (gm/l) 0.08 (0.04–0.29) 0.26 (0.12–0.39) 0.27 (0.13–0.38) <0.001*
SLEDAI score 11 (5–14) 1 (0–2) – <0.001*
Renal SLEDAI 12 (4–12) – – –
Data were expressed in mean ± SD or in median (Min.-Max.).
* Statistically significant at p  0.05.
ba
(*) represents p<0.001, (**) represents p=0.001
Fig. 1. Urinary IP-10 (pg/ml) and CD25 (ng/ml) levels in different groups. (a) Urinary IP-10 (pg/ml) levels in different groups. (b) Urinary sCD25 (ng/ml) levels in different
groups.
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With treatment, 22 patients (from 25 in active nephritis group)
achieved complete (n = 3) or partial (n = 19) remission with the
urinary IP-10 and sCD25 levels decreasing significantly from the
baseline levels. A similar decrease was not found in the other three
patients who did not achieve remission (p = 0.006, p = 0.007
respectively) (Fig. 4). Patients who achieved complete remission
were having classes II and III LN, while all those without remission
were having class IV+V LN.
Follow up urinary IP-10 and sCD25 had a positive significant
correlation with serum creatinine (p = 0.001, p < 0.001), 24 h uri-
nary protein (p = 0.001, p = 0.012) and SLEDAI score (p = 0.001,
p < 0.001).
3.6. ROC curves
Roc curve analysis for urinary IP-10 and sCD25 showed that
both can significantly discriminate between active lupus nephritis
and lupus patients without activity at a cut off level > 2716 pg/ml
for urinary IP-10 with a sensitivity of 88% and specificity of 80%
and at a cut off level > 27.9 ng/ml for sCD25 providing sensitivity
of 84% and specificity of 65% (Table 3), (Fig. 5).4. Discussion
Renal involvement in SLE contributes significantly to patient
morbidity and mortality.19 Hence, it is essential to find a noninva-
sive biomarker that could be used for early diagnosis of LN flares
and for follow up.20 This study illustrated the potential utility of
urinary IP-10 and sCD25 as biomarkers of LN.
We found higher levels of urinary IP-10 and sCD25 in patients
with active nephritis compared to inactive SLE patients and
healthy controls.
CXCL10 promotes migration of T cells to sites of inflammation
and down-regulates angiogenesis, together with its receptor, CXC
receptor 3 (CXCR3).5 In renal transplantation, many studies have
shown the potential role of CXCL10 (IP-10) as an early marker of
acute rejection. Rabant et al.21 concluded that there is an associa-
tion between urinary CXCL10:Cr ratio and tubulointerstitial and
microvascular inflammation of the renal allograft. A lot of studies
assessed serum IP-10 as a marker of active SLE and active lupus
nephritis.22–24 A study by Lit et al.23 showed that plasma concen-
trations of IP-10 were higher in SLE patients than in healthy
individuals.
Similar findings of urinary IP-10 in lupus nephritis were
reported by Marie et al.25 in their study which included thirty
Fig. 2. Correlation between urinary IP-10 (pg/ml) with different parameters.
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lupus nephritis. Avihingsanon et al.26 studied 26 patients with
LN. They examined the urinary mRNA levels of IP-10, CXCR3, trans-
forming growth factor-b (TGF-b), and vascular endothelial growth
factor and concluded that class IV lupus nephritis patients had
higher levels than other classes. Also, Abujam et al.27 studied 136
patients with SLE from whom 78 were active (46 active renal
and 32 active non-renal) finding no difference in serum levels of
monocyte chemoattractant protein 1(MCP-1) and IP-10 between
active renal and active non-renal SLE; only urinary levels were
higher. It seems that the increased urinary excretion of IP-10 in
active LN is mainly due to active local inflammation in the kidneys.
The present study illustrated the correlation between urinary
IP-10 and different activity markers in active lupus nephritis find-
ing a significant positive correlation with serum creatinine, pro-
teinuria, anti ds-DNA, SLEDAI score (global) and renal SLEDAI
score. With follow up, patients who achieved remission had signif-
icant lower levels of urinary IP-10 than baseline levels with persis-
tent or higher levels in patients without remission. This finding
corroborates with that reported by Abujam et al.27 and Avi-
hingsanon et al.26 in their studies. Also, follow up urinary IP-10
showed a positive significant correlation with serum creatinine,
24 h urinary protein and SLEDAI score. However, Abujam et al.27
found no correlation between change in SLEDAI and change in
the IP-10 in the follow up period.Urinary IP-10 levels were highest in class IV LN and lowest in
class II LN and correlated well with activity and chronicity indices
of renal biopsies.
In LN pathogenesis, T lymphocytes have a significant role. IL-2 is
secreted after T-cell activation promoting T cell proliferation by
binding to a high affinity receptor composed of three transmem-
brane proteins, a, b and c chains with CD25 representing the a-
chain of the interleukin-2 receptor (IL-2Ra).28 Many studies
reported that the CD25 region is associated with type1 diabetes
and autoimmune thyroid diseases mainly Graves disease
(GD).29,30 CD25 is highly expressed in CD4+CD25+T regulatory
cells(Tregs) and is important for the production and function of
Tregs, which actively suppress auto reactive T cells in the periph-
ery.31 Serum sCD25 had been studied as a marker of active SLE
and active lupus nephritis by many authors.32,33
In this study, patients with active LN had higher levels of uri-
nary sCD25 than inactive patients and healthy controls. Gupta
et al.34 in their study which included 119 patients [57 active
nephritis (AN), 43 inactive disease (ID), 19 active non renal
(ANR)] collected urine and serum samples for sCD 25 at baseline
from all patients and at 3-monthly follow-up from patients with
AN. Urinary sCD25 values in (AN) at baseline were significantly
higher than inactive and control, but this relation was insignifi-
cant between AN and ANR group. At baseline, mean serum
sCD25 levels for patients in the three groups of patients showed
Fig. 3. Correlation between urinary CD25 (ng/ml) with different parameters.
Table 2










Urinary IP-10 (pg/ml) 2414.5 (1855–2974) 3419 (2721–3684) 4259 (2098–5871) 3006 (2984–3029)
Urinary CD25 (ng/ml) 24.85 (19.40–30.30) 39.8 (21.6–46.3) 55.5 (29.8–60.2) 27.25 (22.7–31.8)
Data were expressed in median (Min.-Max.).
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relate with levels of serum sCD25. Similar findings had been
reported by Tsai et al.35 who studied urine samples from 23
patients with lupus nephropathy (active, inactive) and 15 patients
with proteinuria who did not have (SLE) for the presence of
cytokines, soluble interleukin 2 receptors (sIL-2R), and free light
chain immunoglobulins reporting higher levels of sCD25 in
patients with active nephritis.
The increased urinary sCD25 in active LN is mainly due to local
production by infiltrating mononuclear or mesangial cells in the
inflamed kidney not just filtration from the circulation through
the damaged glomeruli. This is supported by the findings from
studies showing that the urinary not serum levels of sCD25 can dif-
ferentiate active LN from inactive disease.
Like IP-10, we evaluated the correlation between urinary sCD25
and different activity markers in active lupus nephritis finding asignificant positive correlation with serum creatinine, proteinuria,
anti ds-DNA, SLEDAI score (global) and renal SLEDAI score and a
negative significant correlation with C3 and C4. However, Gupta
et al.34 found no correlation between urinary sCD25 and urine pro-
tein:creatinine ratio. Tsai et al.35 stated that, the sIL-2R concentra-
tion in protein from urine was inversely correlated with the 24 h
protein excretion in patients with SLE. Like urinary IP-10, we found
that follow up levels of urinary sCD25 decreased significantly in
patients achieving remission without a similar decrease in those
without remission.
The highest urinary sCD25 levels were in patients with diffuse
proliferative GN (class IV) and the lowest levels were in class II
patients with a good correlation with activity and chronicity
indices of renal biopsies. This might be explained by having more
intense inflammation and more T lymphocyte activation in prolif-
erative classes (III and IV) releasing more sCD25.
a b 
P =0.006 P =0.007
Fig. 4. Relation between response to treatment with urinary IP-10 and urinary CD25 (Follow up).
Table 3
Agreement (sensitivity, specificity) for urinary IP-10 and urinary CD25 to diagnose active LN vs SLE without activity (Group A vs B).
AUC p 95% C.I Cut off Sensitivity Specificity PPV NPV
LL UL
Urinary IP-10 (pg/ml( 0.950 <0.001* 0.893 1.00 >2716 88.0 80.0 84.6 84.2
Urinary CD25 (ng/ml) 0.866* <0.001* 0.764 0.968 >27.9 84.0 65.0 75.0 76.5
AUC: Area under a curve p value: probability value.
CI: Confidence Intervals *: Statistically significant at p  0.05.
PPV: Positive predictive value NPV: Negative predictive value.
a Urinary IP-10 b Urinary CD25
Fig. 5. ROC curve for urinary IP-10 and urinary CD25 to diagnose active LN vs SLE without activity (Group A vs B).
652 M.M.H. Zeid et al. / Alexandria Journal of Medicine 54 (2018) 647–653The strengths of our study are that we are among the earliest to
study the relation between urinary IP-10 and sCD25 with the
histopathological renal class in renal biopsy and the correlation
with the different activity markers of LN. Another strength point
is that we followed up our patients for 3 months and studied the
relation with the response to treatment. Limitations of our study
may be the small sample size and not including active non renal
group.5. Conclusion
Urinary IP-10/CXCL10 and sCD25/ IL-2Ra are potential
biomarkers for early recognition and follow up of lupus nephritis
and are highest in proliferative classes of LN.
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